4 websites get USFDA warning letter for selling illegal opioid medicines

Published On 2019-10-02 04:00 GMT   |   Update On 2019-10-02 04:00 GMT

The networks which were issued the warning letters by USFDA and DEA on Monday for illegally marketing unapproved and misbranded versions of opioid medicines are Divyata, Euphoria Healthcare Pvt Ltd, JCM Dropship and Meds4U, which operate a total of 10 websites.


New Delhi: The U.S. Food and Drug Administration and the Drug Enforcement Administration (DEA) jointly issued warning letters to four online networks for illegally marketing unapproved and misbranded versions of opioid medicines, the agencies said.


The networks which were issued the warning letters on Monday are Divyata, Euphoria Healthcare Pvt Ltd, JCM Dropship and Meds4U, which operate a total of 10 websites.


The move comes at a time when health regulators in the country are combating the rising use of opioids, which were responsible for 47,600 overdose deaths in the United States in 2017.


Also Read: Lupin gets USFDA warning letter for Mandideep Unit-1 facility

Misbranded drugs are those that fail to bear adequate directions for their intended use, the FDA said.


The networks also violated the Controlled Substances Act by not registering the online pharmacies with the DEA despite advertising for the sale of opioids, the agencies said.


In case the online networks fail to take corrective action within 15 working days, the websites’ domain name registrars may be informed, the agencies said.


In June last year, the FDA issued warning letters to nine other online networks operating a total of 53 websites, to stop illegally marketing unapproved versions of opioid medications.


Also Read: Lantech Pharma gets USFDA warning letter for deviations from CGMP at Andhra plant
Article Source : Reuters

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News